Fundraising FoxAdolore Biotherapeutics
Delray Beach, US · Founded 2021 · Delaware corporation
Find your way into Adolore Biotherapeutics
Sign up to see every warm intro you have to Adolore Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adolore Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Adolore Biotherapeutics was founded in 2021 by Roy Levitt.
RR
Roelof RongenChief Executive Officer, Board DirectorRoelof Rongen is an Executive Officer and Director at Adolore Biotherapeutics with more than 25 years of R&D and commercial development experience in the biopharmaceutical industry across oncology, cardiometabolic, autoimmune, and infectious disease areas. He previously contributed to the development of Humira and Lovaza and led Matinas BioPharma through its transition to public markets.
PH
Paul Henry BaroneNamed on SEC filing
LA
Lou AltieriNamed on SEC filing
Board
MR
Mark RogersBoard director
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 3 rounds · 2022–2025
▶$25KraisedSep 2025 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedSep 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul Henry BaroneExecutive Officer, Director, Promoter
- Mark RogersDirector
- Roelof RongenExecutive Officer, Director
- Roy LevittExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $25K
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedJan 2024 · 22 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy LevittExecutive Officer, Director, Promoter
- Paul BaroneExecutive Officer, Director, Promoter
- Roelof RongenExecutive Officer, Director
- Mark RogersDirector
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$250KraisedJan 2022 · 3 investors · BiotechnologyRule 506(b)
▶$250KraisedJan 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy LevittExecutive Officer, Director, Promoter
- Paul BaroneExecutive Officer, Director, Promoter
- Lou AltieriExecutive Officer, Director, Promoter
- Offering amount
- $2.5M
- Amount sold
- $250K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Adolore Biotherapeutics?
- Adolore Biotherapeutics was founded by Roy Levitt in 2021.
- How much funding has Adolore Biotherapeutics raised?
- Adolore Biotherapeutics has disclosed $1.3M raised across 3 rounds.
- Where is Adolore Biotherapeutics headquartered?
- Adolore Biotherapeutics is headquartered in Delray Beach, US.